Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Hires Two New Executives, Wins Patent

Premium

SAN DIEGO--Sequenom has hired Charles Rodi as vice-president, molecular biology, and Paul Heaney as vice-president of advanced systems. Both will report to Charles Cantor, the company's chief scientific officer. Rodi, who had been director of Monsanto's Genomic Sequencing Center, will oversee the advancement of automated assay development systems, such as assays for cost-effective single-nucleotide polymorphism discovery and scoring at Sequenom. Heaney's previous post was at Orchid Biocomputer, as senior director of new technology. In his new role, he will be responsible for R&D of new technologies associated with Sequenom's proprietary DNA MassArray systems.

The company recently received a patent from the US Patent and Trademark Office for its DNA mass array technology, entitled "Bead Linkers for Immobilizing Nucleic Acids to Solid Supports."

Filed under

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.